Patent · US Active

Attenuated strain of myxoma virus for use as an oncolytic drug

US8613915B2 · kind B2 · utility

0Cited by
0References
5Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 11, 2010
Grant dateDec 24, 2013
Priority date
Expiry dateJul 25, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2710/24032
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to the use of an attenuated vaccinal strain of Myxoma virus, in particular the SG33 strain, as an oncolytic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.